Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoaiping is a Chinese patent medicine derived from the extract of Marsdenia tenacissima (Roxb.) Wight et Arn. It is primarily used as an injectable herbal preparation in China for its broad-spectrum anti-tumor properties. Xiaoaiping has been studied and used as an adjunct to chemotherapy in various cancers, including gastric cancer, liver cancer, lung cancer (notably non-small cell lung cancer), breast cancer, and esophageal carcinoma. Its mechanisms are believed to include inhibition of tumor cell proliferation and angiogenesis, enhancement of immune function (such as promoting CD8+ T cell infiltration), downregulation of drug resistance proteins like P-glycoprotein, suppression of vascular endothelial growth factor signaling and protein kinase B pathway in tumor cells, and reduction of inflammatory responses. Clinical studies suggest that Xiaoaiping may improve the efficacy of chemotherapy while reducing adverse effects such as thrombocytopenia and other chemotherapy-induced toxicities[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiaoaiping.